Blueprint Medicines Corp (NASDAQ:BPMC) currently has a daily average trading volume of 621.87K but it saw 931912 shares traded in last market. With a market cap of 6.78B USD, the company’s current market price of $108.30 came rising about 1.19 while comparing to the previous closing price of $107.03. In past 52 weeks, the stock remained buoying in the range of price level as high as $121.90 and as low as $43.89.
Taking a look at 20-day trading activity of Blueprint Medicines Corp (BPMC) gives us an average price of $114.35, while its current price level is -11.16% below from 52-week high level whereas it is 146.75% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $108.76 while that of 200 days or SMA-200 reads an average of $88.42. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.66% during that period while stretching the period over a month that decreases to 3.40%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.55 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Stephens which initiated the stock as “Overweight” in its note to investors issued on May 14, 2024, recommending a price target of $140 for it. Leerink Partners upgraded its recommendation for the stock as a “Market Perform” from “Underperform” on May 06, 2024 while assigning a price target range of $50-$97. Oppenheimer issued its recommendations for the stock as it upgraded the price target for the stock is $85.
Over the week, BPMC’s stock price is moving -5.81% down while it is -0.81% when we observe its performance for the past one month. Year-to-date it is 17.41% up and over the past year, the stock is showing an upside performance of 64.09%.
Currently, Blueprint Medicines Corp’s total number of outstanding shares is 62.62M. Company’s return on investment (ROI) stands at -35.09% and return on equity (ROE) at -79.53%. Stock’s beta reads 0.63. Stock has a price to book (P/B) ratio of 21.82 while price to sale or P/S ratio amounts to 24.03. Its return on asset (ROA) is -25.53% on average.
